Skip to main content
Beat Cancer EU Website Logo
UNICA4EU - Tekoälyn soveltaminen lasten syöpään
EloonjäämisoikeusKaikkiAiheeseen liittyvät hankkeet

UNICA4EU - Tekoälyn soveltaminen lasten syöpään

UNICA4EU - luodaan perusta ekosysteemille, joka helpottaa tekoälyn soveltamista lasten syöpään.

Vuosi:2022

The patient pathway in Childhood Cancer (from diagnosis to treatment and all through to survivorship) is extremely complex and individualised. Despite the tremendous efforts made to set up specific clinical and research frameworks that address the needs of children and young people with cancer, the fact remains that Childhood Cancer is a rare disease. As such, unconnected data silos still exist and this fragmentation is often caused by the lack of a common approach for the definition, application and interconnection of data in the healthcare realm. Artificial Intelligence can be key in bringing a solution to these challenges.

UNICA4EU‘s vision is to lay the foundation of an ecosystem that will facilitate the upscaling and wide-scale application of Artificial Intelligence to Paediatric Cancer in the next ten years, positioning Europe as the worldwide benchmark in the field. The initiative will bring together the multi-disciplinary networks of stakeholders required to strengthen the reference knowledge base for the Paediatric Cancer investigation and promotion. Collaboration is at the very core of UNICA4EU: the team brings together medical and research institutions working on Childhood Cancer, patient, parents and survivor advocacates, cutting-edge expertise in Artificial Intelligence, Machine Learning, bioinformatics and computational biology, and experts in community building and impact creation.

The UNICA4EU project (Grant Agreement 101052609) includes activities to ensure that patients’, survivors’ and parents’ rights regarding data sharing and data use are being protected, and that their needs regarding patient friendly information and education about the use of Artificial Intelligence technologies are met.

Keskustelu & Kysymykset

Huom: Kommentit on tarkoitettu vain keskusteluun ja tarkennuksiin. Lääketieteellisissä asioissa käännythän terveydenhuollon ammattilaisen puoleen.

Jätä kommentti

Vähintään 10 merkkiä, enintään 2000 merkkiä

Ei vielä kommentteja

Ole ensimmäinen, joka jakaa ajatuksensa!